Accelerating Complex Biomarkers, Novel & Multimodal Endpoints to Fuel Drug-Diagnostic Innovations from Bench-to-Bedside for Global Precision Medicine Access
As regulatory headwinds turn to tailwinds, precision medicine is shifting into a new gear.
Evolving FDA approaches to LDTs and 510(k) pathways are removing long-standing friction, coordinated Rx-Dx launches are gaining pace, ctDNA and MRD are advancing as clinically meaningful endpoints, and reimbursement expansion is improving access to high-value genomic testing. At the same time, innovation in multiplex assays, multi-omics platforms, liquid biopsy, digital pathology, spatial biology, and AI-powered diagnostics, are rapidly reshaping the IVD landscape.
Fueled by $60B+ in diagnostic deal-making and strategic partnerships, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns as the industry's esteemed end-to-end precision medicine forum. Convening 850+ senior leaders from biopharma, diagnostic, regulatory, healthcare, testing labs and multimodal communities, with expertise spanning the full value chain, gain the insights, partnerships and insider know-how to prime your team for continued clinical and commercial success.
With the race to bring scalable, accessible drug-diagnostic programs from bench-to-bedside heating up, join us in harnessing the speed, scale, and growing complexity of innovation happening in next-generation IVD platforms, multimodal data, and CDx development.
-
This forum is an industry-targeted event with a very specific focus and I appreciate that this has stayed consistent for the precision medicine community over the years
Global Director, Amgen
-
A great opportunity to network with professionals in the companion diagnostics field and stay informed on the latest trends, emerging technologies and regulatory challenges
Director, Translational Medicine, AstraZeneca
-
This forum forges the opportunity to 1) meet with a diverse group of individuals and organizations working in the CDx space, 2) hear about ongoing efforts, challenges and wins, and 3) connect with key vendors working in the biomarker and CDx space
Head, Translational Medicine, Pfizer
Delve into the Brand-New Agenda
- Free* Attendance for Representatives from Biopharma & Academia
- Your Globally Leading Biomarker & Companion Diagnostics Forum
- Access Numerous Strategic Rx-Dx Co-Development & Partnership Selection Panels
- Partake in Multiple Biomarker Sessions Spanning Oncology, Hematology & Neurological, Chronic, Autoimmune & Rare Diseases
- Discover Brand-New Case Studies on Digital Pathology, Multimodal Data & AI-Enabled Precision Medicine
- Take Advantage of Unmatched, Exclusive Networking & Partnerships Opportunities
A Snapshot of the World-Class Speaker Faculty
Expertise Partners Include
Expect to Connect With
Explore Related Events
Explore the New Agenda
Hear the latest imaging, multi-omics, single-cell and functional assays, enhanced by AI-driven digital biomarker strategies, enabling earlier and smarter treatment decisions for oncology, autoimmune, neurological, chronic and rare disease patients
Partner with Us
Position your solutions alongside leading biomarker, diagnostic and technology providers, to ensure your brand is front and center, and retain your place as the partner of choice in the ever-expanding precision medicine space
Join 850+ Specialist Experts
Be part of the liveliest Rx-Dx conversations with like-minded industry peers spanning a range of precision therapy modalities, and build high-value connections during dedicated networking sessions designed to foster collaborations